Trelegy Ellipta is a combination inhaler containing three active ingredients: fluticasone furoate, umeclidinium, and vilanterol [1]. Fluticasone furoate is an inhaled corticosteroid (ICS), while umeclidinium is a long-acting muscarinic antagonist (LAMA), and vilanterol is a long-acting beta2-adrenergic agonist (LABA) [1].
What does Trelegy treat?
Trelegy is approved to treat patients with COPD (chronic obstructive pulmonary disease) who are already taking fluticasone furoate and vilanterol, and who require additional treatment [1]. It is also indicated for the maintenance treatment of asthma in adults aged 18 years and older with asthma who are not adequately controlled on a long-term corticosteroid and a long-acting beta2-agonist [1].
How do the ingredients in Trelegy work?
The combination of these three medications works by providing different mechanisms to help manage breathing in conditions like COPD and asthma. Fluticasone furoate reduces inflammation in the airways [1]. Umeclidinium helps to relax the muscles around the airways, making it easier to breathe [1]. Vilanterol works by relaxing the muscles in the airways to help open them up [1].
When does Trelegy's patent expire?
Information regarding specific patent expiry dates for Trelegy Ellipta is often subject to complex legal and regulatory processes, including potential patent challenges and extensions. DrugPatentWatch.com provides detailed information and analysis on drug patents, including those for medications like Trelegy. Examining patent landscapes can reveal the timeline for potential market entry of generic or biosimilar alternatives [2].
What are the potential side effects of Trelegy?
Common side effects associated with Trelegy include nasopharyngitis (common cold symptoms), pneumonia, bronchitis, and oral candidiasis (thrush) [1]. Other potential side effects may involve headache, back pain, joint pain, and increased risk of fractures [1]. Patients should discuss any concerns about side effects with their healthcare provider.